Home › Funds › Atlas Venture Life Science Advisors, LLC › KYMR

Atlas Venture Life Science Advisors, LLC position in KYMR

KYMERA THERAPEUTICS INC · Health Care

Atlas Venture Life Science Advisors, LLC reported holding 2,847,541 shares of KYMR (KYMERA THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$318.3M, representing 50.43% of its reported portfolio and ranking #1 among its reported holdings. Atlas Venture Life Science Advisors, LLC has disclosed KYMR holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)2.85M sh
Reported value held$318.33M
Portfolio Weight50.43%
First reportedQ3 2023
Last changeHold
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How Atlas Venture Life Science Advisors, LLC's KYMR position evolved

Atlas Venture Life Science Advisors, LLC first disclosed a stake in KYMR in Q3 2023 at 5,858,262 shares (US$81.4M). The position peaked in Q1 2026 at 4,578,008 shares, worth US$381.3M. Across 13 filings, Atlas Venture Life Science Advisors, LLC increased the stake 0 time(s), trimmed it 6 time(s) and left it unchanged 6 time(s). The most recent filing (Q3 2026) shows 2,847,541 shares valued at US$318.3M. Notable position changes include a 38% trim in Q2 2026 (shares fell 3% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 5.86M $81.43M New
Q4 2023 5.86M $149.15M Hold
Q1 2024 5.38M $216.17M Reduce
Q2 2024 5.35M $159.71M Reduce
Q3 2024 4.90M $231.75M Reduce
Q4 2024 4.90M $196.98M Hold
Q1 2025 4.90M $134.02M Hold
Q2 2025 4.90M $213.68M Hold
Q3 2025 4.90M $277.14M Hold
Q4 2025 4.66M $362.58M Reduce
Q1 2026 4.58M $381.30M Reduce
Q2 2026 2.85M $326.53M Reduce
Q3 2026 2.85M $318.33M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About KYMR and 13F data

KYMR (KYMERA THERAPEUTICS INC) is a Health Care company. 54 other funds we track also report a position in KYMR — the largest reported positions include BAKER BROS. ADVISORS LP (US$992.7M), Avoro Capital Advisors LLC (US$857.1M), T. Rowe Price Investment Management, Inc. (US$717.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding KYMR

All KYMR fund holders →

FAQ

How long has Atlas Venture Life Science Advisors, LLC held KYMR?

Atlas Venture Life Science Advisors, LLC has disclosed KYMR holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is Atlas Venture Life Science Advisors, LLC's current position in KYMR?

As of Q3 2026, Atlas Venture Life Science Advisors, LLC holds 2.85M shares of KYMR (KYMERA THERAPEUTICS INC), valued at $318.33M, representing 50.43% of its reported portfolio and ranking #1.

Has Atlas Venture Life Science Advisors, LLC been buying or selling KYMR?

In the latest 13F filing (Q3 2026), Atlas Venture Life Science Advisors, LLC held unchanged its position in KYMR. The position peaked in Q1 2026 at 4.58M shares.

Which other funds hold KYMR?

Other major institutional holders of KYMR include BAKER BROS. ADVISORS LP, Avoro Capital Advisors LLC, T. Rowe Price Investment Management, Inc., among 54 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.